|
|
 |
About
|
| |
|
Ruga Corporation is an innovative platform-based company focused on discovery and development of novel molecular targets in pathways associated with tumor-selective adaptive responses.
Ruga’s approach is directed against specific molecular targets in tumor metabolism, ER stress response, and tumor microenvironment adaptation pathways which are critical for tumor survival, and which are likely to yield tumor-selective targeted anti-tumor drugs.
The modulation of tumor-selective adaptation responses is a unique approach to cancer therapy and is expected to yield powerful new treatment options either alone or in synergistic combination with other cancer therapies. These novel therapies hold the promise of being more selective than current drugs, thus reducing side effects and offering an improved therapeutic window.
Ruga's current development programs benefit from strong gene-disease linkage which are expected to accelerate drug development and reduce risk by allowing selection of responder patient populations, enabling more focused clinical trials and increasing the likelihood of success by providing clinical biomarkers for tracking patient response.
|
Focused on targeted oncology therapeutics
against key genetic regulators of tumor survival and microenvironment adaptation in endoplasmic reticulum (ER) stress response and tumor metabolism pathways. |
|
Novel oncology programs
in multiple indications in cancer (Lung, Colon, Breast, Prostate, Renal Cell, Ovarian, Multiple Myeloma) with known genetically defined target population indications and molecules with in vivo activity. |
|
Accelerated clinical development
with early proof-of-concept in phase 1b trials possible based on patient-selection and biomarkers strategy. Significant upside for leveraging companion-diagnostics accompanying clinical development. |
|
Broadly applicable scientific platform
engineered to yield a continued supply of diverse novel targets in ER stress and tumor selective metabolic pathways. Biologics and small molecules discovery in oncology and other diseases such as inflammation, lipid metabolism, and neurodegenerative diseases. |
|
|
|
